37 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb
Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR¿ agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nippon Shinyaku
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nippon Shinyaku
Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyorin Pharmaceutical
Synthesis and pharmacological evaluation of novel benzoylazole-based PPARa/κ activators.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dainippon Sumitomo Pharma
Development of a new class of benzoylpyrrole-based PPARa/¿ activators.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dainippon Sumitomo Pharma
A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Seoul National University
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb
Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma a![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
F. Hoffmann-La Roche
Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bayer Pharmaceuticals
Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Tokyo
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Università
Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
The PPARs: from orphan receptors to drug discovery.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxo Wellcome Research & Development
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxo Wellcome Research & Development
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR?)-selective agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Okayama University
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Terns Pharmaceuticals
Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Inception Sciences
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxo Wellcome Research and Development
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Inventiva
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor?/? (PPAR?/?) dual agonists.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The University of Tokyo
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Virginia Commonwealth University